ATM Inhibitor based DNA Damage Response targeting Therapeutic Development Service
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Creative Biolabs' service is designed to provide comprehensive solutions for developing next-generation cancer therapeutics by targeting the ATM-mediated DDR. We offer specific deliverables and problem-solving capabilities to advance your project from concept to preclinical validation. Our expertise allows us to navigate the intricate interplay between ATM inhibition and the tumor microenvironment, including the cGAS-STING-IFNβ pathway and immunosuppressive factors like Galectin-9. We help you identify optimal therapeutic strategies, whether as monotherapy or in rational combinations, to overcome resistance and enhance anti-tumor immunity.
Introduction of ATM Inhibitor-based DNA Damage Response-targeting Therapeutic Development Service
The DNA Damage Response (DDR) is vital for genomic integrity, and its dysregulation is a hallmark of cancer. ATM kinase, a central DDR orchestrator, detects DNA double-strand breaks, initiating repair and cell cycle control. Inhibiting ATM offers a potent strategy for cancer therapy by inducing synthetic lethality in DDR-deficient tumors and sensitizing cancer cells to conventional treatments. Recent research highlights ATM inhibition's complex role in immune modulation, activating anti-tumor immunity while also inducing immunosuppressive factors like Galectin-9, underscoring the need for sophisticated combination strategies.
Discover how we can help - Request a consultation.
What We Can Offer
At Creative Biolabs, we provide biology experts with unparalleled support for their ATM inhibitor-based DDR therapeutic development projects. Our comprehensive, customized solutions accelerate your research and development efforts.
Integrated End-to-End Service
We offer seamless, one-stop solutions from initial target validation and in-depth mechanistic studies to lead optimization and comprehensive preclinical efficacy testing. This integrated approach minimizes hand-offs, reduces vendor management complexities, and significantly streamlines your entire project pipeline, ensuring a cohesive and efficient development journey.
Efficient Development & Robust Preclinical Capabilities
Benefit from efficient compound screening, hit identification, and lead optimization via advanced platforms, ensuring rapid progression. Leverage our extensive in vitro and in vivo models (syngeneic, PDX) for thorough efficacy, safety, and immune-modulating evaluations in challenging tumor types.
Customized Design & High-Standard QC
We offer flexible, customized experimental designs for a wide range of in vitro assays, targeted in vivo studies, or complex combination therapy evaluations. We utilize high-standard quality control tools and rigorous validation assays throughout the process to quantify and evaluate the quality and performance of all products and data generated, ensuring reliability and translational potential for your therapeutic candidates.
Core Steps of ATRi-DDR TDS
Highlights
Integrated End-to-End Solutions
We provide a seamless, integrated workflow that covers every stage from initial target identification and validation through comprehensive preclinical candidate selection.
Deep Scientific & Technical Expertise
We leverage state-of-the-art platforms and advanced technologies for compound screening, structural biology, and next-generation sequencing, ensuring cutting-edge solutions.
Strategic Approach to Complexities
We are uniquely positioned to address the intricate challenges of ATM inhibition, including its dual role in immune modulation (activating anti-tumor immunity while potentially inducing immunosuppressive factors like Galectin-9).
Customized & Results-Driven Partnership
We meticulously tailor our services to meet your unique research objectives and development goals, ensuring maximum efficiency and impact. Our proven track record of successful collaborations demonstrates our dedication to your success.
Experience the Creative Biolabs advantage - Get a quote today.
Customer Reviews
-
Accelerated Discovery
Creative Biolabs' service facilitated the rapid identification and optimization of novel ATM inhibitor candidates. Their high-throughput screening capabilities and medicinal chemistry expertise allowed us to quickly move from hit to lead, significantly shortening our drug discovery timeline. - M***a K.
-
Targeted Precision
We initially struggled to identify a clear strategy for our DDR-targeting therapy. Creative Biolabs' team helped us validate ATM mutation status as a robust predictive biomarker for our compound's efficacy, particularly in challenging indications like pancreatic adenocarcinoma. - P***l R.
FAQs
How does Creative Biolabs identify specific ATM inhibitors?
We employ state-of-the-art high-throughput screening platforms, which allow for the rapid and efficient testing of vast compound libraries against ATM. This is coupled with advanced medicinal chemistry techniques, enabling us to not only identify initial hits but also to iteratively optimize them for enhanced potency, selectivity, and a favorable therapeutic profile.
What efficacy data do you provide?
We provide comprehensive preclinical efficacy data derived from rigorous in vitro and in vivo studies. This includes detailed assessments such as tumor growth inhibition curves, overall survival analyses, and in-depth immunological profiling. Immunological profiling can encompass analyses of immune cell populations, cytokine and chemokine expression, and other markers of immune activation within the tumor and systemic circulation.
How does your service compare to off-the-shelf ATM inhibitors?
Our integrated pipeline goes beyond providing compounds. We offer a tailored solution that includes target validation, novel discovery, optimization, preclinical characterization, combination strategies, and biomarker identification. This holistic approach significantly de-risks and accelerates your drug development compared to fragmented efforts.
Related Services
Creative Biolabs offers a suite of complementary services to support your comprehensive drug discovery and development needs.
Immune Checkpoint Blocking Therapy Development
Our services extend to the discovery and optimization of novel immune checkpoint inhibitors, including those targeting emerging immune checkpoints like TIM-3, as well as established ones like PD-1 and CTLA-4.
Learn More →
Biomarker Discovery
We offer advanced services for identifying, validating, and developing robust diagnostic assays for predictive and prognostic biomarkers.
Learn More →
Preclinical Oncology CRO Services
Our comprehensive in vitro and in vivo preclinical testing capabilities are designed to rigorously evaluate drug efficacy and toxicity, which are particularly valuable for assessing immune-mediated anti-tumor effects.
Learn More →
How to Contact Us
Ready to discuss your project and explore how Creative Biolabs can accelerate your oncology pipeline? We are dedicated to helping you unlock the full therapeutic potential of ATM inhibition, whether as a standalone strategy or as part of powerful combination therapies that overcome resistance and enhance anti-tumor immunity. Contact us for more information and to discuss your project.
For Research Use Only | Not For Clinical Use
